Poniard Pharma (PARD) Reports Progression-Free Survival Data from Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer. The new data demonstrated that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen, and oxaliplatin, given in combination with 5-fluorouracil and leucovorin in the modified FOLFOX-6 regimen, have similar anti-tumor activity in the treatment of first-line metastatic CRC, as assessed by progression-free survival and disease control measured by tumor response rate. New data derived by three independent assessments of neurotoxicity indicated a statistically significant reduction in neurotoxicities with the use of picoplatin in FOLPI compared with oxaliplatin in FOLFOX (p<0.0019).
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- IntercontinentalExchange (ICE) says daily crude volume hits record in May
- Sony (SNE) Said to Pay for 3-D Glasses for 'Men In Black 3' -Bloomberg (RLD)
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
